Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GeoVax Labs, Inc. - Common Stock
(NQ:
GOVX
)
0.3771
-0.0065 (-1.69%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GeoVax Labs, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy
March 03, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Economy
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy
March 03, 2025
GeoVax’s GEO-MVA: Strengthening U.S. Biodefense
Via
TheNewswire.com
Topics
Economy
GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern
February 27, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Death
GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern
February 27, 2025
GeoVax Advancing GEO-MVA Vaccine Candidate to Bolster Global Supply Options
Via
TheNewswire.com
Topics
Death
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
February 18, 2025
GeoVax’s Vaccine Development Programs Align with Anticipated HHS Focus on Vaccine Safety, Diversification and Domestic Biosecurity
Via
TheNewswire.com
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
January 29, 2025
Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness
Via
TheNewswire.com
Topics
Supply Chain
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness
February 24, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness
February 24, 2025
Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax’s MVA-Based GEO-CM04S1 for Enhanced Protection, Particularly for Immunocompromised Populations
Via
TheNewswire.com
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
February 19, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Economy
Supply Chain
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
February 19, 2025
GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness
Via
TheNewswire.com
Topics
Economy
Supply Chain
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
February 18, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
January 15, 2025
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy
Via
TheNewswire.com
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
February 17, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
February 17, 2025
Company to Provide an Update on Its Mpox Vaccine Program
Via
TheNewswire.com
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
February 11, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
February 11, 2025
Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide
Via
TheNewswire.com
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
February 05, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Artificial Intelligence
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
February 05, 2025
Strategic Progress Across COVID-19, Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum
Via
TheNewswire.com
Topics
Artificial Intelligence
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
February 04, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
February 04, 2025
ATLANTA, GA - February 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced...
Via
TheNewswire.com
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
February 03, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Artificial Intelligence
Government
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
February 03, 2025
Harnessing AI to Revolutionize Vaccine and Therapy Development
Via
TheNewswire.com
Topics
Artificial Intelligence
Government
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
January 29, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Supply Chain
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
January 27, 2025
Process Expected to Increase Production Yield, Flexibility at Lower Cost
Via
TheNewswire.com
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
January 27, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
January 15, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
January 13, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
January 13, 2025
Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among Immunocompromised Patients
Via
TheNewswire.com
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
January 08, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
January 08, 2025
Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin® (solid tumor therapy) and GEO-MVA...
Via
TheNewswire.com
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today